Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BNTC Benitec Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: BNTC
Price (delayed)
$13.18
Market cap
$309.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.01
Enterprise value
$230.86M
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It
Highlights
The company's EPS has surged by 91% YoY and by 67% QoQ
The company's quick ratio has surged by 70% QoQ
The company's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of BNTC
Market
Valuations
Earnings
Shares outstanding
23.45M
Market cap
$309.09M
Enterprise value
$230.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$24.09M
Net income
-$21.42M
EBIT
-$20.9M
EBITDA
-$20.55M
Free cash flow
-$21.94M
Per share
Balance sheet
Liquidity
EPS
-$0.01
EPS diluted
-$0.01
Free cash flow per share
-$0.99
Book value per share
$3.27
Revenue per share
$0
TBVPS
$3.58
Total assets
$79.07M
Total liabilities
$3.13M
Debt
$137,000
Equity
$75.94M
Working capital
$75.62M
Debt to equity
0
Current ratio
25.48
Quick ratio
25.37
Net debt/EBITDA
3.81
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-41%
Return on equity
-44.3%
Return on invested capital
N/A
Return on capital employed
-27.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BNTC stock price
How has the Benitec Biopharma stock price performed over time
Intraday
0.3%
1 week
-5.18%
1 month
4.35%
1 year
62.32%
YTD
4.35%
QTD
1.31%
Financial performance
How have Benitec Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.09M
Net income
-$21.42M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
The operating income has declined by 11% year-on-year and by 8% since the previous quarter
BNTC's net income is down by 2.7% since the previous quarter
Price vs fundamentals
How does BNTC's price correlate with its fundamentals
Growth
What is Benitec Biopharma's growth rate over time
Valuation
What is Benitec Biopharma stock price valuation
P/E
N/A
P/B
4.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 91% YoY and by 67% QoQ
BNTC's P/B is 102% above its last 4 quarters average of 2.0 and 26% above its 5-year quarterly average of 3.2
The equity has grown by 18% from the previous quarter
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Benitec Biopharma business performance
Benitec Biopharma's return on equity has surged by 79% YoY and by 29% QoQ
Benitec Biopharma's ROA has soared by 72% YoY and by 25% from the previous quarter
Dividends
What is BNTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BNTC.
Financial health
How did Benitec Biopharma financials performed over time
The company's quick ratio has surged by 70% QoQ
BNTC's current ratio has surged by 70% since the previous quarter
The debt is 100% less than the equity
The debt to equity has plunged by 100% YoY
The debt has plunged by 68% YoY and by 35% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.